Vivian Tambe Ebot-Tar, PharmD, MBA, leads a discussion on value-based care models based on real-world evidence for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA; Jonathan Abbas, MD; Elias Jabbour, MD; James K. McCloskey, MD; Vivian Tambe Ebot-Tar, PharmD, MBA.
The discussants examined the role of value-based care models in optimizing management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Dr Ebot-Tar discussed how such agreements can facilitate access to innovative therapies while aligning costs to outcomes. She shared an example of analyzing real-world chimeric antigen receptor T-cell therapy episode costs and durability to identify opportunities to potentially improve value. Ongoing engagement between payers and research centers provides insights to inform coverage decisions for emerging therapies with still-evolving data. Dr Haumschild concurred that direct provider input helps plans design appropriate medical policies for specialized conditions like Ph+ ALL.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More